Biocatalysis in Large Scale Pharmaceutical Syntheses – Harnessing the Power of Effective Directed Enzyme Evolution


  • Date
    October 7, 2020
  • Time
    8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes

Date : October 7, 2020
Time : 8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes
  • Overview

    Biocatalysis is an important and enabling tool in the syntheses of pharmaceutical molecules. The high degree of selectivity afforded by enzymatic catalysts is well matched to the levels of purity required by pharmaceutical synthesis, and this has been exploited to enable the production of pharmaceutical APIs. Additionally, most enzymes found in nature function effectively in a consistent set of reaction environment parameters (temperature, pressure, pH, solvent). The combination of selectivity, scalability and a common reaction environment also enables large scale tandem processes difficult or impossible to attain with traditional chemistry. Central to realizing the utility of biocatalysis in any of these processes is the ability of enzymes to be tuned to the reaction substrates and conditions required through the process of Directed Evolution. How these properties work together to enable a superior biocatalytic process will be demonstrated through a number of case studies. This webinar will discuss these properties of enzymes and how enzymatic catalysts enable a superior biocatalytic process for API synthesis will be demonstrated through a number of case studies.

    Key Objectives:
    • Key benefits of utilizing enzymatic catalysts to enable complex synthesis for high yield and purity
    • Case studies how evolved enzyme could significantly improve the catalyst efficiency and solve process problems


    Who Should Attend:
    • Process Engineers
    • Process R&D Scientists
    • Enzyme Engineers
    • Drug Development scientists

    Brought to you by:

    STA Pharmaceutical (WuXi STA) and Merck & Co.

  • Speakers

    Dr. Jeffrey Moore
    Sr. Investigator,
    Merck & Co.
    Dr. Jingyang Zhu
    VP of Process Chemistry Enabling Technology,
    STA Pharmaceutical, a WuXi AppTec company (WuXi STA)
    Catherine Dold
    Health & Environment Writer,
    C&EN Media Group